Boom Capital

Diligent Robotics is an A.I. company creating robot assistants that help healthcare workers with routine tasks so they can focus on patient care. Their first robot, Moxi, assists clinical staff in hospitals by handling non-patient-facing tasks.

Fauna Bio is a biotechnology company focused on leveraging the unique adaptations of animals to unlock breakthroughs in human health. They partner with pharmaceutical and biotech companies to explore innovative approaches to difficult disease areas through the lens of human genomics.

Monod Bio is a pioneer company in the design of de novo protein RUO tools, biosensors, and IVD. Our innovative de novo protein design platform takes advantage of the most recent advances in computational protein engineering to create highly modular reporters, binders, and biosensors that enable rapid, sensitive, and inexpensive analytical assays.

Harmonic Discovery leverages machine learning to develop next generation medicines with precision pharmacology, addressing the complexity of disease through rational multi-targeted drug discovery.

Endpoint Health is a company valued at $150M or more, named in Y Combinator's Top Companies list, and launched to assist hospitals in treating critically ill patients.

Synthesis is an educational platform for kids focusing on problem-solving and math tutoring. It offers a curriculum that emphasizes collaborative learning and real-world problem-solving skills.

Impulse Space is developing in-space mobility infrastructure to enable efficient transport of payloads across and between orbits, facilitating commercial, civil, and government missions.

Merlin Labs is an aviation technology company focused on developing autonomous flight systems. It aims to create an AI-powered operating system for aircraft.

Bioptimus is building the first universal foundation model in biology to drive advancements in scientific research and biotechnological innovation. By employing state-of-the-art AI technologies and accessing unique proprietary data, we aim to shape the future of scientific research and improve healthcare outcomes globally.

Olio Labs designs combination therapies that deliver better outcomes with fewer side effects, focusing on improving the efficacy and tolerability of GLP-1 receptor agonists for obesity treatment.

Samaya AI provides expert AI agents designed to streamline financial research, automate workflows, and enhance investment insights with precision and compliance.

Early institutional backer that sources tech from academia and government labs, partnering with scientist- and engineer-led teams to deeply interrogate science, dual-use/defense opportunities, and amplify through an in-house media platform. Explicitly aims to "turn science fiction into science fact" by backing companies at the intersection of the new and the not-yet-imagined, built around scientists, engineers, and polymaths rather than traditional finance backgrounds who can deeply interrogate emerging science and complex tech. The firm systematically mines academia and government labs for "technological gems" and has become one of the earliest institutional backers of dual-use and defense technology.

Early-stage investor in deep-tech—AI, cybersecurity, quantum, robotics, space tech, synthetic biology—with rare bioengineering focus and technically deep partners who engage with complex product and R&D.

Pre-seed lead investor for deeply technical AI, biotech, climatetech and infrastructure startups, offering female operator-led go-to-market expertise and structured fellowships to source technical-founder deal flow. Divergent Capital is run by two female operator-investors who combine deep-tech investing experience with hands-on go-to-market expertise, and they cultivate deal flow through structured fellowships targeting students and emerging investors in their technical-founder network.

A venture firm for builders with $1.5B in total committed capital and a 5000+ member community of ambitious founders. Invests across Pre-Seed, Seed, Series A and Series B+ in deeptech and health sectors.

Harvard's first VC fund that deliberately seeks technically capable founders with liberal-arts backgrounds and nontraditional degrees. Operates through a global network of elite universities where faculty advisers send top students. Aims to change the risk calculus for elite, often first-generation students by providing a credible alternative to consulting and finance jobs, allowing them to become venture-backed CEOs straight out of school.